Skip to main content
Sign In
 

Developmental Therapeutics/Pharmacodynamics Lab


Main Research Focus
Dr. Jimeno's lab is focused on new drug and biomarker development in Head and Neck cancers. Our aim is to bridge the lab and the clinic by 1) developing direct patient xenograft models of head and neck and other cancers to generate better cancer models and as a platform to study cancer stem cells, 2) conducting preclinical tests of targeted agents against de-regulated pathways and cancer stem cells, and 3) devising ways to integrate that knowledge into clinical trials to individualize anti-cancer therapy.

Recent Publications
Keysar SB, Astling DP, Anderson RT, Vogler BW, Paylor JJ, Morton JJ, Paylor JJ, Takimoto SM, Kako SL, Glogowska MJ, Sehrt DB, Le PN, Macfadden SM, Pittman MA, Helber RA, Peterson S, Hausman D, Said S, Robinson WA, Leem TH, Goddard JA, Arcaroli J, Messersmith WA, Hirsch F, Varella-Garcia M, Raben D, Song JI, Wang XJ, Tan AC, Jimeno A. A direct patient tumor model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in the presence of human papillomavirus, and Pi3kca or Notch1 mutations. Mol Oncol 2013.

Keysar SB, Le P, Anderson RT, Astling DP, Vogler BW, Bowles DW, Morton JJ, Paylor JJ, Fernandez P, Glogowska MJ, Thornburn J, Takimoto S, Sehrt D, Bowles DW, Macfadden SM, Pittman MA, Helber RA, Said S, Raben DR, CampbellV, Kutock J, McGovern K, Thornburn A, Song JI, Tan AC, Wang XJ, Jimeno A. The hedgehog pathway influences epidermal growth factor receptor (EGFR) signaling dependence and acquisition of resistance to anti-EGFR therapy in head and neck squamous cell cancer. Cancer Res 2013.

Hong DS, Bowles D, Falchook GS, Messersmith WA, Goldy G, O’Bryant C, Herbst RS, Eckhardt SG, Vo A, Peterson S, Hausman DF, Kurzrock R, Jimeno A. A Phase 1 study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase. Clin Cancer Res 2012.

Jimeno A, Weiss GJ, Miller WH, Gettinger S, Eigl B, Chang ALS, Dunbar J, Devens S, Faia K, Skliris G, Kutok J, Lewis KD, Tibes R, Sharfman WH, Ross RW, Rudin CM. Phase 1 Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors. Clinical Cancer Res 2013.
 
Active Grants
  • NIH R01CA149456
  • NIH R21DE019712
  • Department of Defense CA093422
  • NIH R21CA156114
 
University of Colorado Denver

© The Regents of the University of Colorado, a body corporate. All rights reserved.

All trademarks are registered property of the University. Used by permission only.